59 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
) – June 17, 2024 – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat … is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients
8-K
EX-99.2
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
17, 2024 – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat … company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
for use in connection with this offering.
The Company
We are a biotechnology company dedicated to developing and commercializing innovative solutions … and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel® reverse-thermal hydrogel, a proprietary sustained
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
with this offering.
The Company
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty … to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel® reverse-thermal hydrogel
8-K
EX-99.1
f4rpcwredvh0f5w6p
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
8-K
EX-99.1
dzqmg
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
8-K
EX-99.1
libtzpjru7n
4 Mar 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
7uadnaytzy
7 Feb 24
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
25nser p4q1bp
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
2x2s9n4oug
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am
8-K
EX-99.1
scc xy1bt
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.1
3ukj0e
11 May 23
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
8:05am